Carolinas HealthCare System
Print This Page Print    Email to a Friend Email
Levine Cancer Institute Experts Deliver Industry Leading Cancer Research

May 28, 2015, Chicago, IL--Oncologists from Carolinas HealthCare System's Levine Cancer Institute will present various studies in cancer research to nearly 30,000 physicians from across the globe at the 2015 American Society of Clinical Oncology (ASCO) annual meeting May 29-June 2 in Chicago, IL. The presentations were chosen from thousands of submissions based on their significance and clinical implications for the future of cancer treatment.

In the United States, more than 90 percent of patients do not have access to the newest therapies and treatments. In most cases, patients must live close to a leading cancer center, or have the means to travel, to access cutting-edge new treatment options. Because the Institute’s decentralized model of care and the reach of Carolinas HealthCare System, physicians are able enroll patients in the newest and most promising trials, without the need for long-distance travel.

“Improving care without improving access doesn’t really fix the problem,” said Institute president Derek Raghavan, MD, Phd. “Innovations to increase ready access to new drugs and treatments should be as essential as the development of those drugs and treatments themselves.”

Additional research and outcomes can be followed over the weekend via #ASCO2015. The following Institute physicians will be presenting findings from their research and clinical trials, all focused around emerging treatment options and the latest developments in cancer care:

  • Saad Z. Usmani, MD, Director of Clinical Research in Hematologic Malignancies and Plasma Cell Disorders: “Phase 2 study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM)” (oral presentation: late-breaking abstract).
  • Edward S. Kim, MD, Chair of Solid Tumor Oncology and Investigational Therapeutics: “A phase Ib study of abemaciclib in combination with multiple single agents in stage IV NSCLC” (poster discussion).
  • Jonathan M. Gerber, MD, Director of Leukemia Program: “Correlation of acute myeloid leukemia (AML) stem cell phenotype with cytogenetic/molecular features and prognosis” (oral presentation).
  • Asim Amin, MD, PhD, Co-Director of Immunotherapy Program: “A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM)” (poster discussion)
  • Antoinette Tan, MD, Chief of Breast Medical Oncology: Novel therapies for triple-negative breast cancer” (poster discussion).
  • David Graham, BS, MD: “Twitter, Social Media and Email as Cancer Communication Tools” (oral presentation).


About Carolinas HealthCare System

Carolinas HealthCare System (, one of the nation’s leading and most innovative healthcare organizations, provides a full spectrum of healthcare and wellness programs throughout North and South Carolina. Its diverse network of care locations includes academic medical centers, hospitals, freestanding emergency departments, physician practices, surgical and rehabilitation centers, home health agencies, nursing homes and behavioral health centers, as well as hospice and palliative care services. Carolinas HealthCare System works to enhance the overall health and wellbeing of its communities through high quality patient care, education and research programs, and numerous collaborative partnerships and initiatives.